AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9657784 — intervention group
Group type: COMPARATOR
Intervention: Open mesh hernioplasty
Number of subjects: 400
Study 7807693 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium 1 g/1 g b.i.d.
Number of subjects: 125
Study 7807693 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin sodium 0.5 g/0.5 g q.i.d.
Number of subjects: 125
Study 2665350 — intervention group
Group type: EXPERIMENTAL
Intervention: BS-WC vaccine
Number of subjects: 62285
Study 2665350 — intervention group
Group type: EXPERIMENTAL
Intervention: WC-only vaccine
Number of subjects: 62285
Study 2665350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (K12)
Number of subjects: 62285
Study 15825396 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine, 6 g a day for 2 days prior to challenge and for 7 post-challenge days
Number of subjects: 28
Study 15825396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30935260 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy plus Narrowband UVB plus oral silymarin
Number of subjects: 34
Study 30935260 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy with placebo
Number of subjects: 34
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT group
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular therapy group
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapy group
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS group
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND score and HSI score
Number of subjects: 500
Study 31820598 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 500
Study 28122157 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reflexology intervention
Number of subjects: 0
Study 25774586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/day
Number of subjects: 20
Study 25774586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 20
Study 23532746 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8998 12/16 mg daily
Number of subjects: 216
Study 23532746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10/15 mg daily
Number of subjects: 216
Study 23532746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 23532746 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8998
Number of subjects: 216
Study 23532746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 216
Study 23532746 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8998 and Olanzapine
Number of subjects: 216
Study 21395892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine (2 mg)
Number of subjects: 10
Study 21395892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine (8 mg)
Number of subjects: 10
Study 21395892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine/naloxone (2/0.5 mg)
Number of subjects: 10
Study 21395892 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine/naloxone (8/2 mg)
Number of subjects: 10
Study 21395892 — intervention group
Group type: COMPARATOR
Intervention: Intravenous buprenorphine/naloxone (0.8 mg buprenorphine/0.2 mg naloxone)
Number of subjects: 10
Study 21395892 — intervention group
Group type: EXPERIMENTAL
Intervention: All intranasal doses
Number of subjects: 10
Study 18492551 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery trip CD (experimental group)
Number of subjects: 60
Study 18492551 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 16581623 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-focused (AF) group intervention
Number of subjects: 0
Study 16581623 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship skills-focused (RS) group intervention
Number of subjects: 0
Study 16581623 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (NC)
Number of subjects: 0
Study 12585984 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 266000
Study 10919340 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril wafer
Number of subjects: 16
Study 10919340 — intervention group
Group type: COMPARATOR
Intervention: 20 mg enalapril tablet
Number of subjects: 16
Study 8986932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin retard
Number of subjects: 95
Study 8986932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 95
Study 8986932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 1731452 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 28
Study 6212035 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and gentamicin
Number of subjects: 32
Study 6212035 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin and gentamicin
Number of subjects: 32
Study 31113310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 48
Study 31113310 — intervention group
Group type: COMPARATOR
Intervention: Self-feedback
Number of subjects: 48
Study 31113310 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 48
Study 29862877 — intervention group
Group type: EXPERIMENTAL
Intervention: Illumination at 3 and 4 hours after MAL-application (3/4 group)
Number of subjects: 30
Study 29862877 — intervention group
Group type: COMPARATOR
Intervention: Illumination at 3 and 5 hours after MAL-application (3/5 group)
Number of subjects: 30
Study 28457847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical curettage + adjunct antimicrobial photodynamic therapy (MC + aPDT)
Number of subjects: 54
Study 28457847 — intervention group
Group type: COMPARATOR
Intervention: Mechanical curettage alone (MC)
Number of subjects: 54
Study 26054138 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation applied to Ciliao (BL 32), Shenshu (BL 23), Zigong (EX‐CA 1), Guanyuan (CV 4) and Qihai (CV 6), once a day for 4 weeks.
Number of subjects: 90
Study 26054138 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of midodrine hydrochloride tablets, 2.5 mg per treatment, three times each day for 4 weeks.
Number of subjects: 90
Study 23317780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece Tecnis 1 ZCB00 IOL
Number of subjects: 62
Study 23317780 — intervention group
Group type: COMPARATOR
Intervention: 3-piece Sensar AR40e IOL
Number of subjects: 62
Study 22085421 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention with trained paraprofessional instructor and reinforcement telephone contacts
Number of subjects: 372
Study 22085421 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 372
Study 22085421 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention
Number of subjects: 372
Study 19506195 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-standardized prevalence of dry eye disease (DED) among men 50 years and older
Number of subjects: 25644
Study 19506195 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence of DED
Number of subjects: 25644
Study 19506195 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with DED
Number of subjects: 25644
Study 19506195 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use associated with DED
Number of subjects: 25644
Study 19839175 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal stance test (UPST) with eyes open
Number of subjects: 549
Study 19839175 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal stance test (UPST) with eyes closed
Number of subjects: 549
Study 15671911 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamin C
Number of subjects: 10
Study 15671911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12069109 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300mg per day for four weeks)
Number of subjects: 6
Study 12069109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9793662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine
Number of subjects: 36
Study 9793662 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine
Number of subjects: 36
Study 9793662 — intervention group
Group type: COMPARATOR
Intervention: Placebo-bupivacaine
Number of subjects: 36
Study 9793662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 36
Study 9793662 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 36
Study 7699443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast SPECT technique for stress imaging
Number of subjects: 44
Study 7699443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast SPECT technique for rest imaging
Number of subjects: 44
Study 7699443 — intervention group
Group type: COMPARATOR
Intervention: Standard SPECT technique for stress imaging
Number of subjects: 44
Study 7699443 — intervention group
Group type: COMPARATOR
Intervention: Standard SPECT technique for rest imaging
Number of subjects: 44
Study 2692982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus amikacin
Number of subjects: 27
Study 2692982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 27
Study 2692982 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 27
Study 368852 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis technique (HT)
Number of subjects: 32
Study 368852 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditational relaxation technique (MT)
Number of subjects: 32
Study 368852 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-high responsivity (HT or MT)
Number of subjects: 32
Study 368852 — intervention group
Group type: COMPARATOR
Intervention: Low responsivity HT (Control)
Number of subjects: 32
Study 31026557 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields with average LMiDD ≥0.77 mW/cm3
Number of subjects: 340
Study 31026557 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields with average intensity >1.06 V/cm
Number of subjects: 340
Study 27773846 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography by an emergency department physician
Number of subjects: 1666
Study 27773846 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography by a radiologist
Number of subjects: 1666
Study 27773846 — intervention group
Group type: COMPARATOR
Intervention: Abdominal computerized tomography
Number of subjects: 1666
Study 25813765 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg 3 times a day for 16 weeks)
Number of subjects: 0
Study 25813765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23590451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management (ultrasound scan, maternal serum hPL, induction of labour if either result was abnormal)
Number of subjects: 120
Study 23590451 — intervention group
Group type: COMPARATOR
Intervention: Standard management (ultrasound scan if indicated, induction of labour based on consultant decision)
Number of subjects: 120
Study 23590451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (standard and intensive management)
Number of subjects: 120
Study 21757677 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Number of subjects: 127
Study 21757677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive comparison therapy
Number of subjects: 127
Study 21757677 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study 19209016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (secondary prophylaxis)
Number of subjects: 109
Study 19209016 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic prophylaxis (5-HT3 receptor antagonist and dexamethasone)
Number of subjects: 109
Study 17986903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr-Protein-Carbohydrate (Cr-PRO-CHO) supplement (1.5 g x kg(‐1) body weight x d(‐1) and 0.1 g x kg(‐1) body weight x d(‐1) of creatine)
Number of subjects: 3
Study 17986903 — intervention group
Group type: COMPARATOR
Intervention: Protein-Carbohydrate (PRO-CHO) supplement
Number of subjects: 3
Study 17986903 — intervention group
Group type: COMPARATOR
Intervention: Protein (PRO) supplement
Number of subjects: 3
Study 15249409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve preservation (group A)
Number of subjects: 813
Study 15249409 — intervention group
Group type: COMPARATOR
Intervention: Elective transection (group B)
Number of subjects: 813
Study 15249409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 813
Study 12040275 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (radiation plus chemotherapy)
Number of subjects: 1528
Study 12040275 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (control arm)
Number of subjects: 1528
Study 9660430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized DHEA (25 mg/d)
Number of subjects: 13
Study 7664230 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy very unfavorably
Number of subjects: 447
Study 7664230 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy favorably
Number of subjects: 447
Study 7664230 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians who viewed episiotomy very favorably
Number of subjects: 447
Study 2654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara‐C) at high dose (3.0 g/m2)
Number of subjects: 51
Study 2654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara‐C) at intermediate dose (1.0 g/m2)
Number of subjects: 51
Study 2654790 — intervention group
Group type: COMPARATOR
Intervention: Cytosine arabinoside (Ara‐C) at low dose (0.5 g/m2)
Number of subjects: 51
Study 319122 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (400-mg capsules)
Number of subjects: 0
Study 319122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30369370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 2Hz acupuncture anesthesia (Group A)
Number of subjects: 110
Study 30369370 — intervention group
Group type: COMPARATOR
Intervention: Combined 2Hz/100Hz acupuncture anesthesia (Group B)
Number of subjects: 110
Study 26645242 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 276
Study 26645242 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonosurgery
Number of subjects: 276
Study 26645242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no voice impairment)
Number of subjects: 276
Study 24532471 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-feedback therapy with a bicycle ergometer (once a week for four weeks)
Number of subjects: 78
Study 24532471 — intervention group
Group type: COMPARATOR
Intervention: Routine activities (control group)
Number of subjects: 78
Study 22617224 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 528
Study 22617224 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 528
Study 19539385 — intervention group
Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP) over 7 weeks
Number of subjects: 0
Study 19539385 — intervention group
Group type: EXPERIMENTAL
Intervention: External counterpulsation (ECP)
Number of subjects: 0
Study 17611739 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (2.5 mg)
Number of subjects: 15
Study 17611739 — intervention group
Group type: EXPERIMENTAL
Intervention: pergolide (0.1 mg)
Number of subjects: 15
Study 17611739 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 16518971 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema
Number of subjects: 1001
Study 16518971 — intervention group
Group type: COMPARATOR
Intervention: No-enema
Number of subjects: 1001
Study 11834878 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 15
Study 11834878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10428996 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐EPO five times a week (500 U/kg)
Number of subjects: 80
Study 10428996 — intervention group
Group type: COMPARATOR
Intervention: r‐EPO two times a week (500 U/kg)
Number of subjects: 80
Study 8801107 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms bd
Number of subjects: 847
Study 8801107 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 25 micrograms bd
Number of subjects: 847
Study 8801107 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms bd
Number of subjects: 847
Study 2086265 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior repelling magnet splints
Number of subjects: 20
Study 2086265 — intervention group
Group type: COMPARATOR
Intervention: Acrylic posterior bite‐blocks
Number of subjects: 20
Study 146916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic ethylamide derivative of retinoic acid (Ro. 11‐1430) applied topically for 10 weeks
Number of subjects: 50
Study 146916 — intervention group
Group type: COMPARATOR
Intervention: Topical retinoic acid
Number of subjects: 50
Study 30948567 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 0
Study 30948567 — intervention group
Group type: COMPARATOR
Intervention: fixed CPAP
Number of subjects: 0
Study 28554486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor 90 mg once daily
Number of subjects: 0
Study 28554486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor 45 mg twice daily
Number of subjects: 0
Study 28554486 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel 75 mg
Number of subjects: 0
Study 28554486 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between low-dose ticagrelor groups (90 mg QD and 45 mg BID)
Number of subjects: 0
Study 28554486 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 28554486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg QD
Number of subjects: 0
Study 25650503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 424
Study 25650503 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (150 mg/day)
Number of subjects: 424
Study 25650503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 424
Study 25650503 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 424
Study 25650503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine and Venlafaxine XR
Number of subjects: 424
Study 23199818 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic padded bandage
Number of subjects: 409
Study 23199818 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane heel
Number of subjects: 409
Study 21784096 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise self-regulation intervention
Number of subjects: 725
Study 21784096 — intervention group
Group type: COMPARATOR
Intervention: online questionnaire (control)
Number of subjects: 725
Study 19345831 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) with ethambutol placebo
Number of subjects: 170
Study 19345831 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol (15-20 mg/kg) plus moxifloxacin placebo
Number of subjects: 170
Study 16938698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective memory targets preceded by associated primes
Number of subjects: 0
Study 16938698 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific context instructions provided to participants
Number of subjects: 0
Study 16938698 — intervention group
Group type: COMPARATOR
Intervention: No specific context instructions provided to participants
Number of subjects: 0
Study 15259323 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised landmark task
Number of subjects: 0
Study 15259323 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 11296057 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 128 microg once daily in the morning and placebo in the evening
Number of subjects: 183
Study 11296057 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 128 microg twice daily
Number of subjects: 183
Study 11296057 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 256 microg once daily in the morning and placebo in the evening
Number of subjects: 183
Study 11296057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 9245962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM mangafodipir trisodium infusion (MnDPDP) administered at doses of 5 and 10 mumol/kg b.w. by bolus injection (< 1 min) to 5 subjects and by infusion (20 min) to 8 subjects.
Number of subjects: 13
Study 8320931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent machine haemofiltration
Number of subjects: 30
Study 8320931 — intervention group
Group type: COMPARATOR
Intervention: Continuous hemofiltration and/or dialysis
Number of subjects: 30
Study 3788228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (3 X 200 mg plus 1 X 400 mg daily for one week)
Number of subjects: 12
Study 3788228 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (2 X 150 mg daily for one week)
Number of subjects: 12
Study 31473291 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric Supplementation (CS)
Number of subjects: 230
Study 31473291 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Holidays (DH)
Number of subjects: 230
Study 31473291 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Recovery Treatments (WRT) overall
Number of subjects: 230
Study 31473291 — intervention group
Group type: COMPARATOR
Intervention: CNS Stimulants
Number of subjects: 230
Study 30239134 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Cardiac Rehabilitation (CR) program
Number of subjects: 655